Ashley R Wilson-Smith1,2,3,4,5, Benjamin Muston2,6, Harish Kamalanathan4, Amanda Yung2,3, Cheng-Hao Jacky Chen2,3, Prachi Sahai4, Aditya Eranki4. 1. Department of Thoracic Surgery, The Chris O'Brien Lifehouse Center, Sydney, Australia. 2. Department of Thoracic Surgery, The Collaborative Research Group (CORE), Sydney, Australia. 3. Department of Surgery, The University of Sydney, Sydney, Australia. 4. Department of Surgery, The John Hunter Hospital, Newcastle, Australia. 5. Department of Surgery, The Hunter Medical Research Institute (HMRI), Newcastle, Australia. 6. Faculty of Medicine, University of New South Wales, Sydney, Australia.
Abstract
BACKGROUND: Thoracic endovascular repair (TEVAR) is considered the first-line therapy in the repair of acute complicated type B aortic dissection (AC-BAD). Given the difficulty of designing randomized trials in this surgical cohort, long-term outcome data is limited. This systematic review and meta-analysis provide a complete aggregation of reported long-term survival and freedom from reintervention of AC-BAD patients based on the existing literature. METHODS: Three databases were searched from date of database inception to January 2021. The relevant references were identified and baseline cohort characteristics, survival and freedom from reintervention were extracted. The primary endpoints were survival and freedom from reintervention, whilst secondary endpoints were post-operative outcomes such as cord ischemia and endoleak. Kaplan-Meier curves were digitized and aggregated as per established procedure. RESULTS: A total of 2,812 references were identified in the literature search for review, with 46 selected for inclusion. A total of 2,565 patients were identified, of which 1,920 (75%) were male. The mean age of the cohort was 59.8±5.8. Actuarial survival at 2, 4, 6 and 10 years was 87.5%, 83.2%, 78.5% and 69.7%, respectively. Freedom from all secondary reintervention at 2, 4, 6, 8 and 10 years was 74.7%, 69.1%, 65.7%, 63.9% and 60.9%, respectively. When accounting for study quality, actuarial survival at 2, 4, 6 and 8 years was 85.4%, 79.1%, 69.8% and 63.1%, respectively. Freedom from all secondary reintervention at 2, 4, 6 and 8 years was 73.2%, 67.6%, 63.7% (maintained), respectively. CONCLUSIONS: TEVAR is associated with promising long-term survival extended to 10 years, though rates of freedom from reintervention remain an ongoing point for improvement. Randomized controlled trials comparing endovascular with open repair in the setting of acute, complicated type B aortic dissection are needed. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
BACKGROUND: Thoracic endovascular repair (TEVAR) is considered the first-line therapy in the repair of acute complicated type B aortic dissection (AC-BAD). Given the difficulty of designing randomized trials in this surgical cohort, long-term outcome data is limited. This systematic review and meta-analysis provide a complete aggregation of reported long-term survival and freedom from reintervention of AC-BAD patients based on the existing literature. METHODS: Three databases were searched from date of database inception to January 2021. The relevant references were identified and baseline cohort characteristics, survival and freedom from reintervention were extracted. The primary endpoints were survival and freedom from reintervention, whilst secondary endpoints were post-operative outcomes such as cord ischemia and endoleak. Kaplan-Meier curves were digitized and aggregated as per established procedure. RESULTS: A total of 2,812 references were identified in the literature search for review, with 46 selected for inclusion. A total of 2,565 patients were identified, of which 1,920 (75%) were male. The mean age of the cohort was 59.8±5.8. Actuarial survival at 2, 4, 6 and 10 years was 87.5%, 83.2%, 78.5% and 69.7%, respectively. Freedom from all secondary reintervention at 2, 4, 6, 8 and 10 years was 74.7%, 69.1%, 65.7%, 63.9% and 60.9%, respectively. When accounting for study quality, actuarial survival at 2, 4, 6 and 8 years was 85.4%, 79.1%, 69.8% and 63.1%, respectively. Freedom from all secondary reintervention at 2, 4, 6 and 8 years was 73.2%, 67.6%, 63.7% (maintained), respectively. CONCLUSIONS: TEVAR is associated with promising long-term survival extended to 10 years, though rates of freedom from reintervention remain an ongoing point for improvement. Randomized controlled trials comparing endovascular with open repair in the setting of acute, complicated type B aortic dissection are needed. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Karen M Kim; Carlos E Donayre; Tyler S Reynolds; George E Kopchok; Iwin Walot; Joe P Chauvapun; Rodney A White Journal: J Vasc Surg Date: 2011-08 Impact factor: 4.268
Authors: J Brunkwall; P Kasprzak; E Verhoeven; R Heijmen; P Taylor; P Alric; L Canaud; M Janotta; D Raithel; W Malina; Ti Resch; H-H Eckstein; S Ockert; T Larzon; F Carlsson; H Schumacher; S Classen; P Schaub; J Lammer; L Lönn; R E Clough; V Rampoldi; S Trimarchi; J-N Fabiani; D Böckler; D Kotelis; D Böckler; D Kotelis; H von Tenng-Kobligk; N Mangialardi; S Ronchey; G Dialetto; V Matoussevitch Journal: Eur J Vasc Endovasc Surg Date: 2014-06-22 Impact factor: 7.069
Authors: G Piffaretti; P Ottavi; C Lomazzi; M Franchin; R Micheli; F Ferilli; W Dorigo; M Marrocco-Trischitta; P Castelli; S Trimarchi Journal: Eur J Vasc Endovasc Surg Date: 2017-03-22 Impact factor: 7.069
Authors: Rana O Afifi; Harleen K Sandhu; Samuel S Leake; Mina L Boutrous; Varsha Kumar; Ali Azizzadeh; Kristofer M Charlton-Ouw; Naveed U Saqib; Tom C Nguyen; Charles C Miller; Hazim J Safi; Anthony L Estrera Journal: Circulation Date: 2015-08-25 Impact factor: 29.690